ScreenerHero

MREOMereo BioPharma Group plc

NAS · US · Healthcare · Biotechnology · mereobiopharma.com
0.2904USDMkt Cap: 46.37M $P/E: —

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap46.37M $
Enterprise Value18.00M $
Revenue (TTM)0 $
Gross Profit367.00K $
Net Income (TTM)-41.88M $
Revenue/Share0.0000 USD
Last Price0.2904 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees39
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.45
PEG—
EV/EBITDA-0.56
EV/Revenue—
P/SInfinity
P/B1.63
EPS (TTM)-0.20
EPS (Forward)-0.02
52W Range
0.29031% of range0.3058
52W High0.3058 USD
52W Low0.2903 USD
Profitability
Gross Margin73.40%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-8375.60%
ROE-102.35%
ROA-91.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.97M $
CapEx (TTM)320.00K $
FCF Margin—
FCF Yield-29.45%
Net Debt-29.09M $
Net Debt/EBITDA0.90
Balance Sheet
Debt/Equity0.00
Current Ratio5.88
Quick Ratio5.64
Book Value/Sh0.1800 USD
Cash/Share0.1890 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.015 USD
Upside (mean)+594.0%
Target Range1.009 USD – 3.029 USD
$1.009+594.0% to mean$3.029
# Analysts5
Ownership
Shares Out.159.69M
Float130.82M
Insiders0.75%
Institutions36.08%
Short Interest
Short Ratio3.1d
Short % Float2.63%
Short % Out.2.14%
Shares Short3.41M
Short (prev mo.)5.88M
Technical
SMA 500.3113 (-6.7%)
SMA 2000.6650 (-56.3%)
Beta0.30
S&P 52W Chg21.00%
Avg Vol (30d)688.03K
Avg Vol (10d)18.28M
Technical Indicators
RSI (14)44.2
MACD-0.0028
MACD Signal-0.0017
MACD Hist.-0.0010
BB Upper0.3353 USD
BB Middle0.3072 USD
BB Lower0.2791 USD
BB Width18.28%
ATR (14)0.0272 USD
Vol Ratio (20d)0.07x